Providing therapy with dose administration aids and existing cardiovascular medicines (PAX) - Pilot

The George Institute for Global Health0 个研究点目标入组 100 人开始时间: 2020年11月19日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•Participant inclusion criteria:
•1. Community dwelling adults aged greater than equal to 18 years old
•2. Prescribed at least 5 medicines, with at least 1 cardiovascular indication which includes medications for coronary artery disease, stroke, peripheral vascular disease, hypertension, hypercholesterolaemia, diabetes, arrhythmias, heart failure and valvular heart disease. Broadly this includes Pharmaceutical Benefits Scheme Anatomical Therapeutic Chemical Classifications A10, B01, B02, C01-C10.
•3. Stable medical conditions and stable medications for at least 6 months prior to enrolment
•4. Ability to give informed consent
•Site selection criteria:
•Primary care practices using electronic health records that have the ability to generate practice-level reports of the target population and have regular data extractions performed via MedicineInsight or network processes.

•Participant exclusion criteria:
•1. Responsible primary care or other responsible physician believes it is not appropriate for the patient to participate in the study.
•2. A medical illness, which in the view of the treating physician, has an anticipated life expectancy of less than 8 months.
•3. Patients using any other dose administration aid (e.g. webster pack, automated devices)
•4. Patients with physical disabilities precluding use of the DoseAid (e.g. tearing the sachets) and without a carer to assist them.
•5. Patients with significant cognitive or psychiatric conditions precluding informed consent and use of DoseAid

发起方